Octapharma - clicking the octapharma logo will load the homepage
Terms of use
Octapharma News
The Company
Business Areas
People
Milestones
Financial
Philanthropic Endeavors
8 Questions to Octapharma
Products & Therapeutic Areas
Research & Development
Production
Worldwide Contacts
Career
Expand Menu

 

Milestones


Octapharma's outstanding success is based on innovative products and a careful assessment of market potential, combined with the skills of its people.


1983

Founding of Octapharma

1983
First commercial application of the SD technology for virus inactivation

1985
Octa V.I. low purity FVIII SD virus-inactivated

1987
SD virus-inactivated high-purity Factor VIII

1989
Acquisition of the Vienna plasma fractionation site

1991
World-first SD virus-inactivated, standardised Fresh Frozen Plasma (FFP) for transfusion

1995
World-first SD virus-inactivated liquid, ready-to-use immunoglobulin with a two-year shelf-life at room temperature

1999
Acquisition of the Lingolsheim plasma fractionation plant

2002
Acquisition of Biovitrum's Plasma Business in Sweden

2003
Acquisition of Probifasa SA - a Mexican plasma fractionation company

2003
Opening of Octapharma subsidiaries in USA and Spain

2004
octagam® approved in United States of America

2004

First virus-inactivated universally applicable transfusion plasma
2004
Opening of Octapharma Australia and New Zealand

2005
First double virus-inactivated factor VIII / von Willebrand factor concentrate product

2006
Acquisition of five donor centers in Germany

2007
Opening of first Octapharma donor center in Germany

2008
Acquisition of 12 plasmapheresis centers of Life Therapeutics in the USA.

2008
Contract signed with International BioResources to develop 33 plasma collection centers across the USA.

2008
Opening of Octapharma Italy.

2008
Acquisition of fractionation plant in Springe, Germany, from the German Red Cross.

2009
Octapharma broke the sales record of Euro 1’000 million.